Novocure’s Optune Lua Receives the US FDA’s Nod for Treating Metastatic Non-Small Cell Lung Cancer
Shots:
- The US FDA has approved Optune Lua to be concurrently used with PD-1/PD-L1 inhibitors/docetaxel for treating mNSCLC in adults progressed post Pt-based regimen. It produces TTFields transferred via wearable arrays to disrupt cancer cell division, leading to cell death
- Approval was based on the P-III (LUNAR) trial of Optune Lua used with PD-1/PD-L1 inhibitors/docetaxel vs PD-1/PD-L1 inhibitors/docetaxel alone in mNSCLC patients
- Study showed an mOS of 13.2mos. vs 9.9mos. (3.3mos. increase) with concurrent treatment vs PD-1/PD-L1 inhibitors/docetaxel, 19mos. vs 10.8mos. (8mos. increase) with Optune Lua & a PD-1/PD-L1 inhibitor vs PD-1/PD-L1 inhibitor & 11.1mos. vs 8.9mos. (2.2mos. increase) with Optune Lua & docetaxel vs docetaxel
Ref: Novocure | Image: Novocure
Related News:- Novocure and ZaiLab's Optune Receive NMPA's Approval for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
